Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 83
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Backgroundde Medeiros, L. M., De Bastiani, M. A., Rico, E. P., Schonhofen, P., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Grun, L., Barbé-Tuana, F., Zimmer, E. R., Castro, M. A. A., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1605-3 · Cited by 246
Neuroprotective Herbs for the Management of Alzheimer’s Disease
Gregory, J., Vengalasetti, Y. V., Bredesen, D. E., & Rao, R. V. (2021) · Biomolecules · doi:10.3390/biom11040543 · Cited by 236
A molecular approach in drug development for Alzheimer’s disease
Agatonovic-Kustrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 233
Muhammad, T., Ali, T., Ikram, M., Khan, A., Alam, S. I., & Kim, M. O. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9824-3 · Cited by 200
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 197 · cited 3×
“Degeneration of NBM cholinergic neurons and LC-NE neurons in the basal forebrain is an important cause of AD [11].”
BackgroundGasiorowska, A., Wydrych, M., Drapich, P., Zadrozny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 184 · cited 1×
“In addition, life events related to mental stress and trauma can also lead to accelerated age-related diseases including AD [94].”
BackgroundXu, W., Weissmiller, A. M., White, J. A., Fang, F., Wang, X., Wu, Y., Pearn, M. L., Zhao, X., Sawa, M., Chen, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82409 · Cited by 182 · cited 1×
“Full-length APP and its β-C-terminal fragment lead to nutritional deficiency of BFCNs by increasing activation of Rab5, which leads to early endosomal enlargement and disruption of retrograde nerve growth factor (NGF) signaling and axon transport [48].”
BackgroundBraidy, N., Behzad, S., Habtemariam, S., Ahmed, T., Daglia, M., Nabavi, S. M., Sobarzo‐Sánchez, E., & Nabavi, S. F. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170328113309 · Cited by 177
The GABAergic system as a therapeutic target for Alzheimer's disease
Calvo‐Flores Guzmán, B., Vinnakota, C., Govindpani, K., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14345 · Cited by 171 · cited 1×
“Glutamate and cholinergic dysfunction are known features of AD [51].”
BackgroundFabiani, C., & Antollini, S. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00309 · Cited by 169 · cited 2×
“The main outcome of the pathogenesis of AD is the destruction of cholinergic pathways in the cerebral cortex and basal forebrain [34].”
BackgroundInnovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 159 · cited 2×
“Cholinergic circuits project from the basal forebrain centers to the cerebral cortex and hippocampus [36].”
BackgroundLiu, Z., Li, Z., Liu, L., Tang, W., Wang, Y., Dong, M., & Xiao, C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00261 · Cited by 156
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 143
Moran, S. P., Maksymetz, J., & Conn, P. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.007 · Cited by 142
Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation
Gamage, R. V., Wagnon, I. M., Rossetti, I., Childs, R., Niedermayer, G., Chesworth, R., & Gyengési, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577912 · Cited by 142 · cited 1×
“However, degeneration of central cholinergic neurons may occur, given the anti-inflammatory and antioxidant effects of neuronal glial cholinergic signaling, leading to impaired learning, memory, sleep regulation and attention [29].”
BackgroundMajdi, A., Sadigh‐Eteghad, S., Aghsan, S. R., Farajdokht, F., Vatandoust, S. M., Abbas-Abad, A. N., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 140 · cited 1×
“The abnormal cholinergic system regulates and promotes changes in amyloid precursor protein (APP) metabolism and tau phosphorylation, leading to neurotoxicity, neuroinflammation and neuronal death [37].”
BackgroundProNGF and Neurodegeneration in Alzheimer’s Disease
Fahnestock, M. L., & Shekari, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00129 · Cited by 139 · cited 2×
“The degree of dementia is related to synaptic loss between the basal forebrain and the target tissues of the hippocampus and cortex, which is considered to be the main cause of memory decline [15].”
BackgroundGrothe, M. J., Heinsen, H., Amaro, E., Grinberg, L. T., & Teipel, S. J. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv062 · Cited by 135 · cited 1×
“Neuronal dysfunction in the denervated cortical region mediates degeneration of the basal forebrain cholinergic nucleus, leading to cognitive decline [75].”
BackgroundRapid β-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice
Ramos‐Rodríguez, J. J., Pacheco‐Herrero, M., Thyssen, D. H., Murillo-Carretero, M. I., Berrocoso, E., Spires‐Jones, T. L., Bacskai, B. J., & García-Alloza, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318288a8dd · Cited by 132 · cited 1×
“Acetylcholinesterase (AChE) directly binds to presenilin-1 (PS-1), an important enzyme in the process of Aβ production, and enhances its expression, thereby increasing the level of Aβ, which accelerates cognitive dysfunction [17,18].”
BackgroundCholinergic nervous system and glaucoma: From basic science to clinical applications
Faiq, M. A., Wollstein, G., Schuman, J. S., & Chan, K. C. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.06.003 · Cited by 129
Neuron–astrocyte signaling is preserved in the aging brain
Gómez‐Gonzalo, M., Martin‐Fernandez, M., Martínez‐Murillo, R., Mederos, S., Hernández‐Vivanco, A., Jamison, S., Fernandez, A. P., Serrano, J., Calero, P., Futch, H. S., et al. (2017) · Glia · doi:10.1002/glia.23112 · Cited by 114 · cited 1×
“Astrocytes play a critical role in brain homeostasis, and dysfunction of astrocyte Ca2+ physiology may result in nerves responding to neurotransmitters with Ca2+ elevation and releasing neurotransmitters that activate neuronal receptors and cause degenerative diseases [90].”
BackgroundLi, Y., Fan, H., Sun, J., Ni, M., Zhang, L., Chen, C., Hong, X., Fang, F., Zhang, W., & Ma, P. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105747 · Cited by 114 · cited 5×
“AChEIs can relieve cognitive dysfunction in AD patients through inhibiting the degradation of Ach (Figure 2).”
BackgroundInfluentialMitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
Esteras, N., & Abramov, A. Y. (2020) · Cells · doi:10.3390/cells9092135 · Cited by 113
Jha, A., Panchal, S. S., & Shah, A. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.08.007 · Cited by 107
Classics in Chemical Neuroscience: Donepezil
Brewster, J. T., Dell’Acqua, S., Thach, D. Q., & Sessler, J. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00517 · Cited by 98 · cited 1×
“In particular, PINK 1 is associated with mitochondrial autophagy and cellular protective mitochondrial dysfunction, which may be significant in the pathogenesis of AD [102].”
BackgroundHuperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research
Damar, U., Gersner, R., Johnstone, J. T., Schachter, S. C., & Rotenberg, A. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1175303 · Cited by 97
Labban, S., Alghamdi, B. S., Alshehri, F. S., & Kurdi, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113100 · Cited by 92
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0709-x · Cited by 91 · cited 1×
“In addition to anticholinesterase activity, rivastigmine also guides APP treatment away from BACE1 and toward A secretase [105].”
BackgroundNatural products and their derivatives as multifunctional ligands against Alzheimer's disease
Patil, P., Thakur, A., Sharma, A., & Flora, S. J. S. (2019) · Drug Development Research · doi:10.1002/ddr.21587 · Cited by 84 · cited 1×
“AD can cause a variety of cellular changes, including impaired cholinergic system, Aβ accumulation, tau hyperphosphorylation, dyshomeostasis of metal, neuroinflammation and many other pathways which are related to the pathogenesis of the disease [35,36].”
BackgroundImpact of Altered Cholinergic Tones on the Neurovascular Coupling Response to Whisker Stimulation
Lecrux, C., Sandoe, C. H., Neupane, S., Kropf, P., Toussay, X., Tong, X., Lacalle‐Aurioles, M., Shmuel, A., & Hamel, É. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1784-16.2016 · Cited by 81 · cited 1×
“Ach is not only an effective modulator, but also a necessary condition for the full expression of sensation-induced neurovascular coupling responses [20].”
BackgroundSafar, M. M., Arab, H. H., Rizk, S. M., & El‐Maraghy, S. A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9051-8 · Cited by 79 · cited 1×
“Patients with AD show a decrease in circulating endothelial progenitor cells (EPCs) that repair and maintain endothelial function [93].”
BackgroundGarabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 77 · cited 2×
“The properties of mitochondrial dysfunction (MMP and RCR) were significantly associated with memory formation loss, Aβ levels and cholinergic dysfunction in these animals [4].”
BackgroundDirected differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells
Hu, Y. F., Qu, Z.-Y., Cao, S.-Y., Li, Q., Ma, L., Krencik, R., Xu, M., & Liu, Y. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.03.017 · Cited by 72 · cited 3×
“Basic forebrain cholinergic neurons (BFCNs) are of significance in learning, memory, and cognitive function [12].”
BackgroundInfluentialXhima, K., Markham-Coultes, K., Nedev, H., Heinen, S., Saragovi, H. U., Hynynen, K., & Aubert, I. (2020) · Science Advances · doi:10.1126/sciadv.aax6646 · Cited by 72
Canu, N., Amadoro, G., Triaca, V., Latina, V., Sposato, V., Corsetti, V., Severini, C., Ciotti, M. T., & Calissano, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061319 · Cited by 71 · cited 1×
“Impairment of forebrain cholinergic neurons regulating innate immune responses and inflammation leads to cholinergic dysfunction-related diseases including AD [73].”
BackgroundVenkatesan, R., Subedi, L., Yeo, E., & Kim, S. Y. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.010 · Cited by 67 · cited 1×
“In addition, scopolamine inhibits the secretion of neurotrophic NGF and the growth of neuroblastoma cells, destroys synaptic integrity, mediates c-Jun N-terminal kinase (JNK) activation, and finally leads to synaptic dysfunction, neuroinflammation, and neurodegeneration [70,71].”
BackgroundNicotinic Acetylcholine Receptor Signaling in Neuroprotection
Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 67
Akhtar, A., Bishnoi, M., & Sah, S. P. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.08.001 · Cited by 67 · cited 1×
“Abnormal Aβ is associated with deleterious changes in central cholinergic abnormality during the early stages of AD [44].”
BackgroundAli, B., Jamal, Q. M. S., Shams, S., Al‐Wabel, N. A., Siddiqui, M. U., Alzohairy, M. A., Karawi, M. A. A., Kesari, K. K., Mushtaq, G., & Kamal, M. A. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160321110607 · Cited by 65
AChE and the amyloid precursor protein (APP) – Cross-talk in Alzheimer's disease
Nalivaeva, N. N., & Turner, A. J. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.04.009 · Cited by 62 · cited 1×
“APP is a precursor of Aβ peptide associated with AD, while AChE is related to its pathogenesis by reducing cholinergic deficiency or aggravating Aβ fibrillogenesis and toxicity [104].”
BackgroundSorial, M. E. S., & Sayed, N. S. E. (2017) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-017-1357-4 · Cited by 62 · cited 1×
“In recent studies, interference with insulin receptor desensitization and downstream effects of insulin receptor signaling have been observed in the brains of patients with AD [98].”
BackgroundRole for calcium signaling in manganese neurotoxicity
Ijomone, O. M., Aluko, O. M., Okoh, C. O. A., Martins, A. C., & Aschner, M. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.08.006 · Cited by 61
Montani, C., Canella, C., Schwarz, A. J., Li, J., Gilmour, G., Galbusera, A., Wafford, K. A., Gutierrez‐Barragan, D., McCarthy, A. P., Shaw, D. B., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00916-0 · Cited by 59 · cited 1×
“M1/M4 muscarinic receptors are potential targets of AD [63].”
BackgroundLian, W., Fang, J., Xu, L., Zhou, W., Kang, D., Xiong, W., Jia, H., Liu, A., & Du, G. (2017) · Molecules · doi:10.3390/molecules22030410 · Cited by 58
Kumar, R., Nordberg, A. K., & Darreh‐Shori, T. (2015) · Brain · doi:10.1093/brain/awv318 · Cited by 57 · cited 1×
“High APOE may pathologically alter the biodynamics of Aβ function [50].”
BackgroundChakrabarti, M., McDonald, A. J., Will Reed, J., Moss, M. A., Das, B. C., & Ray, S. K. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150450 · Cited by 57 · cited 1×
“Impairment of retinoic acid signaling can lead to neurodegeneration and progression of AD [99].”
BackgroundKlaassens, B. L., van Gerven, J., Klaassen, E. S., van der Grond, J., & Rombouts, S. A. R. B. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.05.044 · Cited by 55 · cited 1×
“Damage to the cholinergic system may lead to increased cerebellar default mode network connectivity in AD [58].”
BackgroundBiased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs
Bradley, S. J., Molloy, C., Valuskova, P., Dwomoh, L., Scarpa, M., Rossi, M., Finlayson, L., Svensson, K. A., Chernet, E., Barth, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0453-9 · Cited by 55
Agrawal, M., Perumal, Y., Bansal, S., Arora, S., & Chopra, K. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111684 · Cited by 54
Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice
Zhou, J., Yang, W.-S., Suo, D.-Q., Li, Y., Peng, L., Xu, L.-X., Zeng, K.-Y., Ren, T., Wang, Y., Zhou, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00389 · Cited by 53 · cited 1×
“Scopolamine acted on the brain region and reduced the protein expressions of phosphorylated Akt, ERK1/2 and CREB in the hippocampus, resulting in impaired memory and learning ability and significantly reduced hippocampal cholinergic system reactivity and neurogenesis [68].”
BackgroundGarcez, M. L., Jacobs, K. R., & Guillemin, G. J. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00057-3 · Cited by 52 · cited 2×
“However, other pathophysiological features of AD have emerged, including neuroinflammation and dysregulation of the kynurenine pathway (KP) [92].”
BackgroundThe Natural Product Curcumin as a Potential Coadjuvant in Alzheimer's Treatment
Morales, I., Cerda-Troncoso, C., Andrade, V., & Maccioni, R. B. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170354 · Cited by 51 · cited 1×
“6 million people worldwide are living with the disease [6].”
BackgroundTiernan, C. T., Ginsberg, S. D., He, B., Ward, S., Guillozet-Bongaarts, A. L., Kanaan, N. M., Mufson, E. J., & Counts, S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.021 · Cited by 51 · cited 1×
“Dysregulation of neurotrophic and neurotransmitter signal transduction is an early pathogenic mechanism, which is related to NFT formation in fragile BNM neurons and cognitive decline in AD [80].”
BackgroundIshola, I. O., Jacinta, A. A., & Adeyemi, O. O. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00409-0 · Cited by 51 · cited 2×
“The increasing number of aging populations globally increases the incidence of chronic degenerative diseases, central nervous system damage and dementia such as AD [7].”
BackgroundGeorge, A. A., Vieira, J. M., Xavier-Jackson, C., Gee, M. T., Cirrito, J. R., Bimonte‐Nelson, H. A., Picciotto, M. R., Lukas, R. J., & Whiteaker, P. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0876-20.2020 · Cited by 51 · cited 1×
“Hyperexcitability at the neuronal and network levels is usually associated with elevated Aβ levels [42].”
BackgroundChang, W., Pedroni, A., Bertuzzi, M., Kızıl, Ç., Simon, A., & Ampatzis, K. (2021) · Nature Communications · doi:10.1038/s41467-021-25052-1 · Cited by 51 · cited 1×
“Pharmacological stimulation of cholinergic receptors and interference with GABAergic signals can promote functional recovery after spinal cord injury [65].”
BackgroundAcetylcholinesterase Modulates Presenilin-1 Levels and γ-Secretase Activity
Campanari, M., García‐Ayllón, M., Belbin, O., Galcerán, J., Lleó, A., & Sáez‐Valero, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140426 · Cited by 48 · cited 1×
“Acetylcholinesterase (AChE) directly binds to presenilin-1 (PS-1), an important enzyme in the process of Aβ production, and enhances its expression, thereby increasing the level of Aβ, which accelerates cognitive dysfunction [17,18].”
BackgroundLi, H., Jia, X., Qi, Z., Fan, X., Ma, T., Ni, H., Li, C. R., & Li, K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00127 · Cited by 47
Lipid mapping of the rat brain for models of disease
Martínez‐Gardeazabal, J., Román, E. G. D. S., Moreno‐Rodríguez, M., Llorente‐Ovejero, A., Manuel, I., & Rodríguez‐Puertas, R. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.02.011 · Cited by 46 · cited 1×
“For example, different kinds of phosphatidylcholine, phosphatidic acid, phosphoinositol and phosphatidylserine are differently distributed in different locations of gray matter and white matter [33].”
BackgroundPersonalized genetics of the cholinergic blockade of neuroinflammation
Simchovitz, A., Heneka, M. T., & Soreq, H. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13928 · Cited by 46 · cited 2×
“The cognitive and inflammatory aspects of cholinergic signaling are mediated by CholinomiRs by targeting major cholinergic transcripts including acetyl cholinergic hydrolase AChE [22].”
BackgroundPaz, M. L., & Barrantes, F. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00041 · Cited by 44 · cited 1×
“In the central nervous system, nAChR is involved in the pathological mechanism of neurodegenerative diseases such as AD [59].”
BackgroundAdiponectin and sporadic Alzheimer’s disease: Clinical and molecular links
Letra, L., Rodrigues, T., Matafome, P. N., Santana, I. J., & Seiça, R. M. F. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.002 · Cited by 43 · cited 1×
“Obesity has long been associated with AD, although the exact mechanism by which it affects cognition remains elusive and is the subject of current research [97].”
BackgroundZheng, H. Y., Niu, S., Zhao, H., Li, S., & Jiao, J. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0303-6 · Cited by 43
Thompson, K. J., & Tobin, A. B. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109545 · Cited by 42 · cited 1×
“worldwide, and is characterized by cognitive decline and has long been associated with dysregulation of the cholinergic system [9,10].”
BackgroundTriaca, V., & Calissano, P. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.193224 · Cited by 40 · cited 1×
“This is also true in the case of altered NGF in sporadic AD, an age-related pathology characterized by cholinergic loss, amyloid plaques, and neurofibrillary tangles [85].”
BackgroundKwakowsky, A., Milne, M., Waldvogel, H. J., & Faull, R. L. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122122 · Cited by 40 · cited 1×
“BFCNs are involved in many cognitive functions, including attention, learning and memory, and are particularly vulnerable in AD [74].”
BackgroundMufson, E. J., He, B., Ginsberg, S. D., Carper, B. A., Bieler, G. S., Crawford, F., Alvarez, V. E., Huber, B. R., Stein, T. D., McKee, A. C., et al. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5368 · Cited by 40 · cited 1×
“P-tau is the major component of neuro-fibrous tangles (NFTs), and the accumulation of intracellular abnormal p-tau can lead to chronic traumatic encephalopathy (CTE) [41].”
BackgroundYu, H. W., Yuan, B., Chu, Q., Wang, C., & Bi, H. C. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4058 · Cited by 40
Yan, Y.-H., Li, S.-H., Gao, Z., Zou, S.-F., Li, H.-Y., Tao, Z.-Y., Song, J., & Yang, J.-X. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.004 · Cited by 38
Ren, Z., Yang, M., Guan, Z.-Z., & Yu, W. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181022093359 · Cited by 37 · cited 1×
“Endogenous astrocytic α b-crystallin (Cryab) represses Aβ aggregation through regulation of nAChR activation and PI3K/Akt signal transduction in α7 neurons [61].”
BackgroundAlldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2018) · Hippocampus · doi:10.1002/hipo.22832 · Cited by 36
Messiha, B. A. S., Ali, M. R. A., Khattab, M. M., & Abo‐Youssef, A. M. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00724-4 · Cited by 36 · cited 1×
“Compounds derived from alkaloids of plant phytochemicals could be used to treat AD, such as galantamine and carboplatin, to restore the decline of the cholinergic system [103].”
BackgroundThangnipon, W., Puangmalai, N., Soi‐ampornkul, R., Suwanna, N., Tuchinda, P., & Nobsathian, S. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.215262 · Cited by 35
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35
Cholinergic neurodegeneration in Alzheimer disease mouse models
Shekari, A., & Fahnestock, M. L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00013-7 · Cited by 33 · cited 1×
“Basal forebrain is the primary output site of cholinergic energy in the central nervous system [28].”
BackgroundGao, H., Li, C., Nabeka, H., Shimokawa, T., Wang, Z., Cao, Y., & Matsuda, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160093 · Cited by 32 · cited 1×
“Pathological features of AD also include neurofibrillary tangles (NTF) formation, synaptic dysfunction, and neuron loss [39,40].”
Backgroundβ-Amyrin Ameliorates Alzheimer's Disease-Like Aberrant Synaptic Plasticity in the Mouse Hippocampus
Park, H. J., Kwon, H., Lee, J., Cho, E., Lee, Y. C., Moon, M., Jun, M., Kim, D. H., & Jung, J. W. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.024 · Cited by 32 · cited 1×
“Alzheimer’s disease, the most common type of dementia, is a progressive and commonly diagnosed neurodegenerative disease [1] with a very high mortality rate, which is closely related to genetic factors and age.”
BackgroundRen, Z., Dong, Z., Xie, P., Lv, J., Hu, Y., Guan, Z.-Z., Zhang, C., & Yu, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11132 · Cited by 32
Functionally selective and biased agonists of muscarinic receptors
Randáková, A., & Jakubík, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105641 · Cited by 32 · cited 1×
“Disruption of cholinergic signals through muscarinic receptors has been associated with various pathologies including AD [62].”
BackgroundTao, L.-X., Huang, X., Chen, Y., Tang, X.-C., & Zhang, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.78 · Cited by 31 · cited 1×
“Iron balance disorder of iron dyshomeostasis is one of the main causes of neuronal death in AD [88].”
BackgroundCafé-Mendes, C. C., Garay-Malpartida, M., Malta, M. B., Lima, L. D. S., Scavone, C., Ferreira, Z. S., Markus, R. P., & Marcourakis, T. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.056 · Cited by 31 · cited 3×
“The hippocampus is severely affected in diseases with neuroinflammatory components such as AD [14].”
BackgroundInfluentialSingh, S. P., & Gupta, D. K. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.04.002 · Cited by 31 · cited 1×
“In neuronal signaling, human acetylcholinesterase (AChE) is an important enzyme, responsible for the degradation of ACh, which in turn blocks postsynaptic signal transmission (Figure 1) [23].”
BackgroundMitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer’s Disease
Wu, A. J., Tong, B. C., Huang, S., Li, M., & Cheung, K. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191210091302 · Cited by 31 · cited 1×
“Significant memory loss and cognitive decline are associated with neuronal death and gray matter loss, especially in the frontal cortex and hippocampus [84].”
BackgroundKelley, C. M., Ginsberg, S. D., Alldred, M. J., Strupp, B. J., & Mufson, E. J. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22700 · Cited by 30 · cited 1×
“In Down’s syndrome (DS) or trisomy 21, and AD-induced diseases, the BFCN projection system shows a degraded feature [77].”
BackgroundMcKeever, P. M., Kim, T. P., Hesketh, A. R., MacNair, L., Miletic, D., Favrin, G., Oliver, S. G., Zhang, Z., George‐Hyslop, P. S., & Robertson, J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.014 · Cited by 29
Huang, X., Wang, C., Chen, L., Zhang, T., Leung, K. L., & Wong, G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166203 · Cited by 29 · cited 1×
“found in lesions associated with age-related neurodegenerative disease including AD [46].”
BackgroundGhoshal, A., Moran, S. P., Dickerson, J. W., Joffe, M. E., Grueter, B. A., Xiang, Z., Lindsley, C. W., Rook, J. M., & Conn, P. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00167 · Cited by 27 · cited 1×
“Increased GABAa-dependent inhibitory tension in PFC pyramidal neurons leads to cortical disruption and schizophrenia [64].”
BackgroundOlasehinde, T. A., Olaniran, A. O., & Okoh, A. I. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00469-2 · Cited by 27 · cited 1×
“Zn treatment significantly reduced the level of glutathione and the activities of superoxide dismutase and catalase [87].”
BackgroundSun, Y., Wu, A., Li, X., Qin, D., Jin, B., Liu, J., Tang, Y., Wu, J., & Yu, C. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1697298 · Cited by 27
Multimodal Encoding of Novelty, Reward, and Learning in the Primate Nucleus Basalis of Meynert
Martínez‐Rubio, C., Paulk, A. C., McDonald, E. J., Widge, A. S., & Eskandar, E. N. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2021-17.2017 · Cited by 26 · cited 3×
“It is a forebrain agent that has currently been shown to be therapeutic in improving ischemic stroke, traumatic brain injury, Parkinson’s disease, AD, and cerebrovascular disease.”
BackgroundInfluentialLatina, V., Caioli, S., Zona, C., Ciotti, M. T., Borreca, A., Calissano, P., & Amadoro, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00487 · Cited by 26
Stem Cell-Derived Neurons as Cellular Models of Sporadic Alzheimer’s Disease
Foveau, B., Correia, A. S., Hébert, S. S., Rainone, S., Potvin, O., Kergoat, M., Belleville, S., Duchesne, S., & LeBlanc, A. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180833 · Cited by 25 · cited 1×
“AD occurs in the form of autosomal dominant or sporadic genetic diseases [8].”
BackgroundEivani, M., Alijanpour, S., Arefian, E., & Rezayof, A. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.107065 · Cited by 25 · cited 2×
“Memory formation increases BDNF and p-CREB/CREB in PFC, the hippocampus and amygdala [30].”
BackgroundEndocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer’s Disease
Llorente‐Ovejero, A., Manuel, I., Lombardero, L., Giralt, M. T., Ledent, C. A., Giménez‐Llort, L., & Rodríguez‐Puertas, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180137 · Cited by 24 · cited 1×
“AD is characterized by progressive memory decline associated with selective impairment of cholinergic neurotransmission [66].”
BackgroundEstrogen Protects Neurotransmission Transcriptome During Status Epilepticus
Iacobaş, D. A., Iacobaş, S., Nebieridze, N., Velíšek, L., & Velíšková, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00332 · Cited by 24
Li, L., Xu, S., Liu, L., Feng, R., Gong, Y., Zhao, X., Li, J., Cai, J., Feng, N., Wang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160587 · Cited by 23 · cited 1×
“Homeostasis of transition metal ions is believed to be related to the pathogenesis of AD [86].”
BackgroundAlzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels
Fukunaga, K., Izumi, H., Yabuki, Y., Shinoda, Y., Shioda, N., & Han, F. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.11.014 · Cited by 22
Xia, E., Xu, F., Hu, C., Kumal, J. P. P., Tang, X., Mao, D., Li, Y., Wu, D., Zhang, R., Wu, S., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.010 · Cited by 22
Kim, S., Ko, Y., Lee, S., & Jang, C. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111160 · Cited by 22
Varshney, V., & Garabadu, D. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102122 · Cited by 22 · cited 1×
“Aβ42 significantly reduced the expression level of heme oxygenase-1 in various brain regions of rats [45].”
BackgroundFarhat, S. M., & Ahmed, T. (2016) · Current Drug Targets · doi:10.2174/1389450117666161005145143 · Cited by 21 · cited 1×
“The localization of Aβ plaques, particularly in regions rich in cholinergic neurons, led to the discovery that Aβ binds to a7 nAChRs with high affinity [47].”
BackgroundAnni, D., Weiss, E., Guhathakurta, D., Akdaş, E. Y., Klueva, J., Zeitler, S., Andres‐Alonso, M., Huth, T., & Fejtová, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03835-5 · Cited by 21 · cited 1×
“This process enhances neuroplasticity and memory formation by increasing presynaptic release of neurotransmitters [27].”
BackgroundMachhi, J., Sinha, A., Patel, P. S., Kanhed, A. M., Upadhyay, P. N., Tripathi, A., Parikh, Z. S., Chruvattil, R., Pillai, P. P., Gupta, S. S., et al. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9598-4 · Cited by 20
Yin, W., Mamashli, F., Buhl, D. L., Khudyakov, P., Volfson, D., Martényi, F., Gevorkyan, H., Rosen, L. B., & Simen, A. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14975 · Cited by 20
Ishola, I. O., Olubodun-Obadun, T. G., Ojulari, M. A., & Adeyemi, O. O. (2020) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2020-0118 · Cited by 19
Soto‐Mercado, V., Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201045 · Cited by 19
Mohamed, R. A., Abdallah, D. M., El-Brairy, A. I., Ahmed, K. A., & El-Abhar, H. S. (2021) · Molecules · doi:10.3390/molecules26165068 · Cited by 19
Thomsen, M. S., Andreasen, J. T., Arvaniti, M., & Kohlmeier, K. A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160127112357 · Cited by 18
Frinchi, M., Scaduto, P., Cappello, F., Belluardo, N., & Mudò, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26454 · Cited by 18 · cited 1×
“The cholinergic system has a crucial role in regulating neurogenesis, neuronal differentiation, synaptic plasticity and neuroprotection in the central nervous system [26].”
BackgroundSystemic Immune Dyshomeostasis Model and Pathways in Alzheimer’s Disease
Talwar, P., Kushwaha, S. S., Gupta, R., & Agarwal, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00290 · Cited by 18
Early and Late Pathomechanisms in Alzheimer’s Disease: From Zinc to Amyloid-β Neurotoxicity
Szutowicz, A., Bielarczyk, H., Zyśk, M., Dyś, A., Ronowska, A., Gul‐Hinc, S., & Klimaszewska‐Łata, J. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2154-z · Cited by 17 · cited 1×
“Intracellular zinc overload hits several neuronal targets, leading to energy balance breakdown and impaired function and structural damage of cholinergic neurons [67].”
BackgroundJiang, H., Liao, T., Zhong, G., Zhang, J., Chen, Y., Wang, Q., & Zeng, Q.-P. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170417111420 · Cited by 16
Schwarthoff, S., Tischer, N., Sager, H., Schätz, B., Rohrbach, M. M., Raztsou, I., Robaa, D., Gaube, F., Arndt, H., & Winckler, T. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116355 · Cited by 16 · cited 1×
“AD is associated with cognitive dysfunctions such as memory loss caused by progressive deficits in cholinergic and glutamate signaling in the central nervous system [53].”
BackgroundMuramatsu, I., Yoshiki, H., Uwada, J., Masuoka, T., Sada, K., Taniguchi, T., & Nishio, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13843 · Cited by 15 · cited 1×
“In human brain, ACh is absorbed by a special transport system that has different pharmacological properties from the known organic cation transporters [25].”
BackgroundYegla, B., & Parikh, V. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.08.017 · Cited by 15 · cited 2×
“Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD [31].”
BackgroundHu, Z., Yang, Y., Gao, K., Rudd, J. A., & Fang, M. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2868 · Cited by 14
Sato, T., Ohi, Y., Kato, D., Mizuno, M., Takase, H., Kanamori, T., Borlongan, C. V., Haji, A., & Matsukawa, N. (2017) · Cell Transplantation · doi:10.1177/0963689717721232 · Cited by 14
Gene expression profiling of midbrain dopamine neurons upon gestational nicotine exposure
Kanlikilicer, P., Zhang, D., Dragomir, A., Akay, Y. M., & Akay, M. (2016) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-016-1531-8 · Cited by 13 · cited 1×
“Most of the significantly up-regulated/downregulated genes found in DA neurons are related to G-protein-coupled protein receptor signaling and development [100].”
BackgroundSemwal, B. C., & Garabadu, D. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1767136 · Cited by 13 · cited 1×
“Moreover, Aβ significantly reduced mitochondrial function, integrity, and bioenergetics in all brain regions of mice [49].”
BackgroundLlorente‐Ovejero, A., Martínez‐Gardeazabal, J., Moreno‐Rodríguez, M., Lombardero, L., Román, E. G. D. S., Manuel, I., Giralt, M. T., & Rodríguez‐Puertas, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00169 · Cited by 13 · cited 1×
“The loss of BFCNs can lead to impaired cholinergic neurotransmission, abnormal synaptic function and changes in structural lipid metabolism [76].”
BackgroundGiil, L. M., Aarsland, D., Hellton, K. H., Lund, A., Heidecke, H., Schulze‐Forster, K., Riemekasten, G., Vik‐Mo, A. O., Kristoffersen, E. K., Vedeler, C. A., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170882 · Cited by 12 · cited 1×
“Endogenous antibodies to signal molecules and receptors are associated with AD [83].”
BackgroundSadananda, G., & Subramaniam, J. R. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135666 · Cited by 12 · cited 1×
“Neurotransmitters and their signaling are impaired in patients with AD [52].”
BackgroundBuján, A., Lister, J. J., O’Brien, J. L., & Edwards, J. D. (2019) · Psychophysiology · doi:10.1111/psyp.13466 · Cited by 11 · cited 1×
“The identification of neurophysiological biomarkers of mild cognitive impairment (MCI) will contribute to the detection and tracking of the progression of cognitive impairment [69].”
BackgroundNicotinic receptor modulation of the default mode network
Hahn, B., Harvey, A. N., Concheiro, M., Huestis, M. A., Ross, T. J., & Stein, E. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05711-9 · Cited by 11 · cited 1×
“Low nAChR pitch has a causal role in DMN dysregulation seen in conditions such as mild cognitive impairment and AD [60].”
BackgroundOlivé, I., Makris, N., Densmore, M., McKinnon, M. C., & Lanius, R. A. (2021) · Human Brain Mapping · doi:10.1002/hbm.25454 · Cited by 11 · cited 1×
“Individuals with post-traumatic stress disorder (PTSD) are also a risk of developing various forms of dementia [95].”
BackgroundFahimi, A., Noroozi, M., & Salehi, A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819975-6.00011-x · Cited by 7
[Nicotinic acetylcholine receptor in Alzheimer's disease].
Abe, K. (2013) · PubMed · Cited by 6
Tadalafil Reversed H-89 – and Scopolamine – Induced Spatial Learning Impairments in Male Rats
Tabrizian, K., Amelinia, F., Belaran, M., Pourheidar, S., Mirzaei, H., & Fanoudi, S. (2021) · Drug Research · doi:10.1055/a-1345-7832 · Cited by 5 · cited 1×
“Moreover, a scopolamine analogue H-89, as an inhibitor of protein kinase, can significantly reduce spatial learning ability, such as H-89-induced spatial learning disorder in male rats [72].”
BackgroundGoshadrou, F., & Sadeghi, B. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112608 · Cited by 2 · cited 1×
“Electrical stimulation of NBM or irbotulin-induced NBM damage in rats has been found to lead to ADd-like neuropathic memory loss [78].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“98 These cell bodies of neurons are predominantly located in the medial septal nucleus (MSN), diagonal band of broca (DBB), NBM, and substantia innominata (SI).”
BackgroundTeleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596
“Furthermore, as acetylcholine can regulate the normal cholinergic signal transduction (associated with learning and memory), its low levels in AD patients are no surprise, being manifested through damaged cholinergic signal transduction and cognitive impairment [11,104].”
BackgroundAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Self-citationThe duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 190
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
“It is important to recognize that AD not only inflicts irreversible and severe damage to the quality of life and mental well-being of patients, but also imposes significant economic and medical burdens on their families and society as a whole [234].”
Background
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.